Research archive for JNJ

Johnson & Johnson (J&J) has been a Vestact recommended stock since 2012. Over those 13 years it has returned around 150%, underperforming the S&P500 which was up 316% in the same period. Thanks to multiple lawsuits, a lack of innovative products and a complacent corporate culture, the J&J share price has even underperformed inflation over the last 5 years. We can do better.

Johnson & Johnson reported quarterly results last week for the period ending December 2024. At first glance they looked solid, with decent revenue gains in both their pharma and their medical device units.

Johnson & Johnson started the year with a bang after announcing a $14.6 billion buy-out of listed company Intra-Cellular Therapies. J&J is paying a 39% premium to Friday's closing price for the biotech company that specialises in products for the central nervous system.

Johnson & Johnson is always the first Vestact stock to release earnings for the season. Not exactly the most exciting business but sometimes a bit of boring in a portfolio is a good thing. This quarter saw a solid beat on sales and earnings, but they lowered full-year guidance slightly. That didn't seem to deter the market, the stock ended up 1.5% on a day when most other shares were down.

Johnson & Johnson is making a third attempt to settle the flimsy claims that its talc products caused cancer. J&J denies the allegations, and they are medically unfounded, but it faces over 62 000 claims. At this point, they are just trying to make them go away.

Johnson & Johnson jumped 3.7% on a tough day for markets after reporting second-quarter numbers that beat revenue and profit expectations. Second-quarter sales came in at $22.4 billion reflecting a 4.2% year-on-year. Adjusted earnings for the quarter were $2.82 per share, 11 cents above analysts' estimates.

The Johnson & Johnson share price has been a disappointment over the last 18 months, basically flat while the market has soared. I was encouraged to see them announcing a deal last week to buy Shockwave Medical for $13 billion.

Yesterday, Johnson & Johnson posted results before the US market opened. The company reported better revenue and profit than analysts were expecting, thanks to stronger growth from both the pharmaceutical and medical devices divisions. There isn't a consumer division anymore due to the spin-off of Kenvue in the middle of last year.

Clients have been a little anxious about Johnson & Johnson because it hasn't done much over the last five years. It's been grinding slowly higher, unlike the tech stocks that we own, which have been flying. J&J does have a 3% dividend yield, which is nice. Apart from that, there's not been much to "write home about", as they say.

Johnson & Johnson (J&J) reported solid third quarter numbers yesterday. They earned $2.66 per share, versus the $2.52 that was expected. Sales for the quarter were $21.4 billion, up 6.8% year-on-year.

Johnson & Johnson reported strong second-quarter numbers last week, with increased revenue and profit thanks to a surge in heart procedures and higher demand for cold and flu medicines. The share price popped 6% on the day.

Yesterday, Johnson & Johnson kicked off earnings season for Vestact stocks on a decent note. Revenues came in at $24.7 billion, well above the consensus of $23.6 billion. Earnings per share also had a nice beat, posting $2.68 versus $2.49 expected.

Johnson & Johnson is probably our most boring recommended stock. The company itself has many exciting products, but the share price just plods along, paying out a decent dividend. Due to this stability, J&J was one of our only holdings last year to post positive returns. The reason for their predictable earnings is that they have three major divisions that dovetail nicely with each other. Each quarter, at least one of the parts does well.

Vestact-recommended pharma giant Johnson & Johnson (J&J) reported better-than-expected third-quarter numbers on Tuesday thanks to strong demand from its prescription drug unit. Revenues for the quarter were $23.79 billion, up 1.9% year-on-year and topping estimates. On the other hand, the management team remains concerned about the strong US Dollar and inflation.

Yesterday, before the US market opened, Johnson & Johnson reported their quarterly results. The company is a bit boring but consistent, trotting along with steady and stable growth. Thanks to this predictability, the J&J share price has held all of its value this year, even with the broader market being down about 20%.